|
1
|
Protocol for the Examination of specimens
from Patients with Carcinomas of the Lip and Oral Cavity.
https://cap.objects.frb.io/protocols/cp-headandneck-lip-oralcavity-17protocol-4001.pdfMay
1–2017
|
|
2
|
Lindenblatt Rde C, Martinez GL, Silva LE,
Faria PS, Camisasca DR and Lourenço Sde Q: Oral squamous cell
carcinoma grading systems-analysis of the best survival predictor.
J Oral Pathol Med. 41:34–39. 2012. View Article : Google Scholar
|
|
3
|
Bhargava A, Saigal S and Chalishazar M:
Histopathological grading systems in oral squamous cell carcinoma:
A review. J Int Oral Health. 2:1–9. 2010.
|
|
4
|
Brandwein-Gensler M and Smith RV:
Prognostic indicators in head and neck oncology including the new
7th edition of the AJCC staging system. Head Neck Pathol. 4:53–61.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zwetyenga N, Majoufre-Lefebvre C,
Siberchicot F, Demeaux H and Pinsolle J: Squamous-cell carcinoma of
the tongue: Treatment results and prognosis. Rev Stomatol Chir
Maxillofac. 104:10–17. 2003.(In French). PubMed/NCBI
|
|
6
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnson R and Halder G: The two faces of
Hippo: Targeting the Hippo pathway for regenerative medicine and
cancer treatment. Nat Rev Drug Discov. 13:63–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baldwin C, Garnis C, Zhang L, Rosin MP and
Lam WL: Multiple microalterations detected at high frequency in
oral cancer. Cancer Res. 65:7561–7567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dupont S, Morsut L, Aragona M, Enzo E,
Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M,
Bicciato S, et al: Role of YAP/TAZ in mechanotransduction. Nature.
474:179–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sanz-Moreno V, Gaggioli C, Yeo M,
Albrengues J, Wallberg F, Viros A, Hooper S, Mitter R, Féral CC,
Cook M, et al: ROCK and JAK1 signaling cooperate to control
actomyosin contractility in tumor cells and stroma. Cancer Cell.
16:229–245. 2011. View Article : Google Scholar
|
|
11
|
Aragona M, Panciera T, Manfrin A, Giulitti
S, Michielin F, Elvassore N, Dupont S and Piccolo S: A mechanical
checkpoint controls multicellular growth through YAP/TAZ regulation
by actin-processing factors. Cell. 154:1047–1059. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao B, Wei X, Li W, Udan R, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barry ER, Morikawa T, Butler BL, Shrestha
K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, et
al: Restriction of intestinal stem cell expansion and the
regenerative response by YAP. Nature. 493:106–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu X, Yang N, Figel SA, Wilson KE,
Morrison CD, Gelman IH and Zhang J: PTPN14 interacts with and
negatively regulates the oncogenic function of YAP. Oncogene.
32:1266–1273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang JM, Nagatomo I, Suzuki E, Mizuno T,
Kumagai T, Berezov A, Zhang H, Karlan B, Greene MI and Wang Q: YAP
modifies cancer cell sensitivity to EGFR and survivin inhibitors
and is negatively regulated by the non-receptor type protein
tyrosine phosphatase 14. Oncogene. 32:2220–2229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Neel BG and Tonks NK: Protein tyrosine
phosphatases in signal transduction. Curr Opin Cell Biol.
9:193–204. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gyapay G, Morissette J, Vignal A, Dib C,
Fizames C, Millasseau P, Marc S, Bernardi G, Lathrop M and
Weissenbach J: The 1993–94 Généthon human genetic linkage map. Nat
Genet. 7:246–339. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ogata M, Takada T, Mori Y, Uchida Y, Miki
T, Okuyama A, Kosugi A, Sawada M, Oh-hora M and Hamaoka T:
Regulation of phosphorylation level and distribution of PTP36, a
putative protein tyrosine phosphatase, by cell-substrate adhesion.
J Biol Chem. 274:20717–20724. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wadham C, Gamble JR, Vadas MA and
Khew-Goodall Y: Translocation of protein tyrosine phosphatase
Pez/PTPD2/PTP36 to the nucleus is associated with induction of cell
proliferation. J Cell Sci. 113:3117–3123. 2000.PubMed/NCBI
|
|
20
|
Wyatt L, Wadham C, Crocker LA, Lardelli M
and Khew-Goodall Y: The protein tyrosine phosphatase Pez regulates
TGFbeta, epithelial-mesenchymal transition, and organ development.
J Cell Biol. 178:1223–1235. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishimi Y: A DNA helicase activity is
associated with an MCM4, −6, and −7 protein complex. J Biol Chem.
272:24508–24513. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Labib K, Tercero JA and Diffley JF:
Uninterrupted MCM2-7 function required for DNA replication fork
progression. Science. 288:1643–1647. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lo Sardo F, Forcato M, Sacconi A, Capaci
V, Zanconato F, Di Agostino S, Del Sal G, Pandolfi PP, Strano S,
Bicciato S and Blandino G: MCM7 and its hosted miR-25, 93 and 106b
cluster elicit YAP/TAZ oncogenic activity in lung cancer.
Carcinogenesis. 38:64–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Szelachowska J: Różnice w długości
przeżycia chorych na płaskonabłonkowego raka dna jamy ustnej lub
trzonu języka w zależności od poziomu ekspresji białka MCM7, RB,
E-kadheryny, p16, TGFb i PTPN14 w komórkach guza. (Wrocław).
Uniwersytet Medyczny im. Piastów Śląskich. 2015.(In Polish).
|
|
25
|
Edge S, Byrd D, Compton C, Fritz A, Greene
F and Trotti A: AJCC Cancer Staging Manual. (7th). Springer. (New
York, NY). 2010.
|
|
26
|
National Comprehensive Cancer Network.
Bone Cancer (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf2019
05 07
|
|
27
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.PubMed/NCBI
|
|
28
|
Leemans CR, Tiwari R, Nauta JJ, van der
Waal I and Snow GB: Recurrence at the primary site in head and neck
cancer and the significance of neck lymph node metastases as a
prognostic factor. Cancer. 73:187–190. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gueiros LA, Coletta RD, Kowalski LP and
Lopes MA: Clinicopathological features and proliferation markers in
tongue squamous cell carcinomas. Int J Oral Maxillofac Surg.
40:510–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tamura T, Shomori K, Haruki T, Nosaka K,
Hamamoto Y, Shiomi T, Ryoke K and Ito H: Minichromosome
maintenance-7 and geminin are reliable prognostic markers in
patients with oral squamous cell carcinoma: Immunohistochemical
study. J Oral Pathol Med. 39:328–334. 2010.PubMed/NCBI
|
|
31
|
Feng CJ, Li HJ, Li JN, Lu YJ and Liao GQ:
Expression of Mcm7 and Cdc6 in oral squamous cell carcinoma and
precancerous lesions. Anticancer Res. 28:3763–3769. 2008.PubMed/NCBI
|
|
32
|
Torres-Rendon A, Roy S, Craig GT and
Speight PM: Expression of Mcm2, geminin and Ki67 in normal oral
mucosa, oral epithelial dysplasias and their corresponding
squamous-cell carcinomas. Br J Cancer. 100:1128–1134. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Szelachowska J, Dziegiel P,
Jelen-Krzeszewska J, Jelen M, Matkowski R, Pomiecko A, Spytkowska
B, Jagas M, Gisterek I and Kornafel J: Mcm-2 protein expression
predicts prognosis better than Ki-67 antigen in oral cavity
squamocellular carcinoma. Anticancer Res. 26:2473–2478.
2006.PubMed/NCBI
|
|
34
|
Michaloglou C, Lehmann W, Martin T,
Delaunay C, Hueber A, Barys L, Niu H, Billy E, Wartmann M, Ito M,
et al: The tyrosine phosphatase PTPN14 is a negative regulator of
YAP activity. PLoS One. 8:e619162013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang W, Huang J, Wang X, Yuan J, Li X,
Feng L, Park JI and Chen J: PTPN14 is required for the
density-dependent control of YAP1. Genes Dev. 26:1959–1971. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wilson KE, Li YW, Yang N, Shen H, Orillion
AR and Zhang J: PTPN14 forms a complex with Kibra and LATS1
proteins and negatively regulates the YAP oncogenic function. J
Biol Chem. 289:23693–23700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ehsanian R, Brown M, Lu H, Yang XP,
Pattatheyil A, Yan B, Duggal P, Chuang R, Doondeea J, Feller S, et
al: YAP dysregulation by phosphorylation or ΔNp63-mediated gene
repression promotes proliferation, survival and migration in head
and neck cancer subsets. Oncogene. 29:6160–6171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ge L, Smail M, Meng W, Shyr Y, Ye F, Fan
KH, Li X, Zhou HM and Bhowmick NA: Yes-associated protein
expression in head and neck squamous cell carcinoma nodal
metastasis. PLoS One. 6:275292011. View Article : Google Scholar
|
|
39
|
Jerhammar F, Johansson AC, Ceder R,
Welander J, Jansson A, Grafström RC, Söderkvist P and Roberg K:
YAP1 is a potential biomarker for cetuximab resistance in head and
neck cancer. Oral Oncol. 50:832–839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Z, Wang Y, Zhu Y, Yuan C, Wang D, Zhang
W, Qi B, Qiu J, Song X, Ye J, et al: The Hippo transducer TAZ
promotes epithelial to mesenchymal transition and cancer stem cell
maintenance in oral cancer. Mol Oncol. 9:1091–1105. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zheng L, Xiang C, Li X, Guo Q, Gao L, Ni
H, Xia Y and Xi T: STARD13-correlated ceRNA network-directed
inhibition on YAP/TAZ activity suppresses stemness of breast cancer
via co-regulating Hippo and Rho-GTPase/F-actin signaling. J Hematol
Oncol. 30:722018. View Article : Google Scholar
|
|
42
|
Cottini F, Hideshima T, Xu C, Sattler M,
Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri
A, et al: Rescue of Hippo coactivator YAP1 triggers DNA
damage-induced apoptosis in hematological cancers. Nat Med.
20:599–606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Attisano L and Wrana JL: Signal
integration in TGF-β, WNT, and Hippo pathways. F1000Prime Rep.
5:172013. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Azzolin L, Panciera T, Soligo S, Enzo E,
Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V,
et al: YAP/TAZ incorporation in the β-catenin destruction complex
orchestrates the Wnt response. Cell. 158:157–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the Roots of Cancer. Cancer Cell. 13:783–803. 2016.
View Article : Google Scholar
|
|
46
|
Levy D, Adamovich Y, Reuven N and Shaul Y:
Yap1 phosphorylation by c-Abl is a critical step in selective
activation of proapoptotic genes in response to DNA damage. Mol
Cell. 29:350–361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Calvo F, Ege N, Grande-Garcia A, Hooper S,
Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary
E, Charras G and Sahai E: Mechanotransduction and YAP-dependent
matrix remodelling is required for the generation and maintenance
of cancer-associated fibroblasts. Nat Cell Biol. 15:637–646. 2013.
View Article : Google Scholar : PubMed/NCBI
|
